- Home
- GRFS vs ELP Comparison
GRFS vs ELP Comparison
Compare GRFS & ELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFS
- ELP
- Stock Information
- Founded
- GRFS 1940
- ELP 1954
- Country
- GRFS Spain
- ELP Brazil
- Employees
- GRFS N/A
- ELP N/A
- Industry
- GRFS Biotechnology: Pharmaceutical Preparations
- ELP Electric Utilities: Central
- Sector
- GRFS Health Care
- ELP Utilities
- Exchange
- GRFS Nasdaq
- ELP Nasdaq
- Market Cap
- GRFS 7.2B
- ELP 6.2B
- IPO Year
- GRFS 2006
- ELP 1997
- Fundamental
- Price
- GRFS $10.72
- ELP $8.91
- Analyst Decision
- GRFS Hold
- ELP
- Analyst Count
- GRFS 1
- ELP 0
- Target Price
- GRFS $10.30
- ELP N/A
- AVG Volume (30 Days)
- GRFS 1.3M
- ELP 338.2K
- Earning Date
- GRFS 01-01-0001
- ELP 08-06-2025
- Dividend Yield
- GRFS 1.33%
- ELP 4.95%
- EPS Growth
- GRFS 132.60
- ELP 30.24
- EPS
- GRFS 0.53
- ELP 0.19
- Revenue
- GRFS $8,744,226,659.00
- ELP $4,381,150,343.00
- Revenue This Year
- GRFS $5.40
- ELP N/A
- Revenue Next Year
- GRFS $6.74
- ELP $6.56
- P/E Ratio
- GRFS $25.84
- ELP $11.55
- Revenue Growth
- GRFS 9.32
- ELP 8.47
- 52 Week Low
- GRFS $6.19
- ELP $5.72
- 52 Week High
- GRFS $11.14
- ELP $9.34
- Technical
- Relative Strength Index (RSI)
- GRFS 66.35
- ELP 52.17
- Support Level
- GRFS $10.40
- ELP $8.95
- Resistance Level
- GRFS $10.84
- ELP $9.34
- Average True Range (ATR)
- GRFS 0.32
- ELP 0.22
- MACD
- GRFS -0.04
- ELP 0.04
- Stochastic Oscillator
- GRFS 73.91
- ELP 56.93
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
About ELP Companhia Paranaense de Energia (COPEL) (each representing one Unit consisting one Common Share and four non-voting Class B Preferred Shares)
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.